The study identified several genetic mutations associated with drug resistance in Mycobacterium tuberculosis strains from Russia, including mutations in rpoB, katG, embB, pncA, rrs, rpsL, ethA, ndhA, Rv0194, Rv1634, and Rv2688c, which confer resistance to rifampicin, isoniazid, ethambutol, pyrazinamide, kanamycin, amikacin, streptomycin, ethionamide, and fluoroquinolone.

The paper discusses the identification of drug resistance determinants in Mycobacterium tuberculosis using whole-genome sequencing, highlighting the importance of mutations in genes such as rpoB, katG, inhA, pncA, embCAB, gyrA, gyrB, atpE, rrs, rpsL, ald, ethA, and thyX. It also identifies new resistance-associated mutations in ethA and the thyX promoter.

The study identifies multiple AMR genes and mutations associated with ethionamide, streptomycin, isoniazid, ethambutol, pyrazinamide, rifampicin, fluoroquinolones, terizidone, cycloserine, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis strains.

Indels in Mycobacterium tuberculosis are significantly enriched in antibiotic resistance genes, contributing to the evolution of multidrug resistance in an outbreak. Specific genes like pncA, mmaA3, ethA, espK, and nudC were identified as being disrupted by indels, leading to resistance against pyrazinamide, isoniazid, and ethionamide.

The study identifies mutations in antibiotic resistance genes such as embB, katG, gyrA, ethA, and pncA that contribute to resistance in Mycobacterium tuberculosis complex during active disease.

The study identifies several mutations in Mycobacterium tuberculosis that confer resistance to various antibiotics, including isoniazid, rifampicin, streptomycin, fluoroquinolones, pyrazinamide, ethionamide, bedaquiline, clofazimine, and kanamycin. These mutations were found to evolve over five years of treatment in a patient with inadequate compliance.

The study identifies IS6110-mediated gene disruptions in clinical Mycobacterium tuberculosis strains that lead to resistance against bedaquiline, clofazimine, ethionamide, pyrazinamide, and para-aminosalicylic acid.

The study identified ethA, inhA, and P fabG1 as key molecular determinants of ethionamide resistance in Mycobacterium tuberculosis clinical isolates.

The study identifies several genes associated with drug resistance in Mycobacterium tuberculosis, including rpoB, katG, rpsL, embB, gidB, gyrA, ethA, rpoC, Rv1730c, Rv1830, treY, cyp128, and eccCa1, which show evidence of positive selection and are linked to resistance against various antibiotics.

The study reports the first identification of extensively drug-resistant Mycobacterium tuberculosis clinical isolates with resistance to bedaquiline, linezolid, and clofazimine in Uganda, highlighting the importance of adherence to treatment and the need for improved surveillance and diagnostics.

The study identified several genes and mutations associated with drug resistance in Mycobacterium tuberculosis, including rpoB, ethA, mmpL3, and prrB, which are linked to resistance against rifampicin, ethionamide, and various compounds. Additionally, mutations in genes like Rv0678, mbtA, and sugI were found to contribute to resistance against bedaquiline, clofazimine, and D-cycloserine.

The study identified multiple AMR genes and mutations in Mycobacterium tuberculosis variant bovis strains from Mato Grosso, Brazil, including resistance to pyrazinamide, isoniazid, rifampicin, streptomycin, ethambutol, ethionamide, fluoroquinolones, kanamycin, capreomycin, paraminosalicylic acid, cycloserine, bedaquiline, linezolid, and delamanid.

The study presents a targeted next-generation sequencing (tNGS) assay for detecting drug-resistant Mycobacterium tuberculosis directly from clinical specimens, demonstrating high concordance with whole genome sequencing (WGS) results and significantly reducing turnaround time compared to traditional methods.

The study identified various AMR genes and mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Latvia, highlighting discrepancies between phenotypic and genotypic DST results for certain drugs.

The study identifies specific genetic mutations in MDR Ural lineage Mycobacterium tuberculosis strains in Moldova, including rpoB S450L, rpsL K88R, ethA H281P, and murA R110T, which are associated with resistance to rifampin, streptomycin, ethionamide, and potential compensatory resistance to rifampin, respectively.

The study identifies several genes and mutations associated with drug resistance in Mycobacterium tuberculosis, including pncA, ethA, ndh, mshA, embR, rpoB, inhA, gyrA, and Rv0678, along with their respective mutations that confer resistance to pyrazinamide, ethionamide, isoniazid, rifampicin, ethambutol, fluoroquinolones, bedaquiline, and clofazimine.